-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Reiterates Buy on Revolution Medicines, Raises Price Target to $261

Benzinga·11/05/2026 16:02:09
Truist Securities analyst Gregory Renza reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $241 to $261.